Document Detail


Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay.
MedLine Citation:
PMID:  21054593     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: patient co-payments for prescription medicines in Wales were abolished in April 2007 and there has been much speculation on the possible effects. We analysed patient-reported use of medicines before and after abolition of the prescription charge, noting changes in the number of items prescribed, number of non-prescription medicines purchased and participants not collecting all prescribed items (primary non-adherence).
METHODS: a sample of community pharmacists across Wales (n = 249) issued questionnaires to customers at the point of dispensing who were not exempt from the prescription charge. A second questionnaire was delivered by post to those who returned the first questionnaire (n = 1027) and expressed a willingness to participate further. Paired t-tests were applied to responses from those completing both questionnaires (n = 593). Further analyses were carried out according to gender, age and reported levels of household income.
KEY FINDINGS: there was a statistically significant (P = 0.03) rise in the number of items prescribed, and a statistically significant fall (P = 0.02) in the number of non-prescription medicines purchased. Primary non-adherence was also found to fall between pre- and post-abolition periods. Those most affected in terms of increase in number of prescribed items prescribed were the older age group (45-59 years), and those with household income of between £15600 and £36400. The most affected in the fall in number of medicines purchased were males, those in the lower age group (25-34 years) and those with a higher household income (>£36400).
CONCLUSIONS:  although the rise in number of items prescribed and fall in number of medicines purchased was generally anticipated, there appeared to be little or no effect for those on the lowest incomes.
Authors:
Sam Groves; David Cohen; M Fasihul Alam; Frank D J Dunstan; Philip A Routledge; Dyfrig A Hughes; Susan Myles
Related Documents :
17887743 - Chemical markup, xml, and the world wide web. 7. cmlspect, an xml vocabulary for spectr...
22230833 - Systematic review and meta-analysis of practice facilitation within primary care settings.
21935663 - Impacts of species interactions on grass community productivity under contrasting manag...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-05
Journal Detail:
Title:  The International journal of pharmacy practice     Volume:  18     ISSN:  0961-7671     ISO Abbreviation:  Int J Pharm Pract     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-08     Completed Date:  2011-01-04     Revised Date:  2011-03-03    
Medline Journal Info:
Nlm Unique ID:  9204243     Medline TA:  Int J Pharm Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  332-40     Citation Subset:  IM    
Affiliation:
Health Economics and Policy Research Unit, Faculty of Health Sport and Science, University of Glamorgan, Mid Glamorgan, UK. sgroves@glam.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Distribution
Cost Sharing / economics*
Female
Health Care Surveys
Humans
Income / statistics & numerical data
Male
Medication Adherence / statistics & numerical data*
Middle Aged
Nonprescription Drugs / economics,  therapeutic use
Pharmacies / economics
Prescription Drugs / economics*,  therapeutic use
Prescription Fees / statistics & numerical data*
Questionnaires
Sex Distribution
Wales
Chemical
Reg. No./Substance:
0/Nonprescription Drugs; 0/Prescription Drugs
Comments/Corrections
Erratum In:
Int J Pharm Pract. 2011 Feb;19(1):79

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Practice and attitudes regarding the management of childhood diarrhoea among pharmacies in Thailand.
Next Document:  Classification, location and legitimacy of web-based suppliers of Viagra to the UK.